论文部分内容阅读
法国最近已批准巴斯德研究所生产的胎牛肾细胞疫苗(FBKCV)用于狂犬病暴露后治疗。作者报告了法国东北部狂犬病流行区两个治疗中心所获得的结果。本研究对象均符合下列条件:(1)咬人动物经实验室证实罹患狂犬病;(2)患者从未接受过狂犬病疫苗免疫;(3)患者愿意使用此疫苗;(4)在被咬伤后两周内开始治疗。153例患者(女43例,男110例)接受了FBKCV。疫苗批号03,NIH法效力为10IU/ml。其中35例<29岁(13～29岁),64例为
France has recently approved the Pasteur Kidney Cell Vaccine (FBKCV) produced by the Pasteur Institute for post-exposure rabies exposure. The authors report on the results obtained from two treatment centers for rabies endemic areas in northeastern France. The subjects met the following criteria: (1) Rabbit bites were laboratory verified; (2) Rabbits were never immunized against rabies vaccine; (3) Patients were willing to use the vaccine; (4) Begin treatment within two weeks. 153 patients (43 females and 110 males) received FBKCV. Vaccine batch number 03, NIH method efficacy of 10IU / ml. Of these, 35 were <29 years old (13-29 years) and 64 were